In mammals, implantation, the period during which the blastocyst establishes an intimate connection with the uterus, is essential for embryonic development. In preparation for implantation, the uterus undergoes a series of changes, primarily driven by the ovarian steroid hormones that culminate in the uterus becoming transiently receptive to blastocysts. In mice, receptivity commences on the morning of the fourth day after mating (day of plug = day 1 pregnancy), with implantation, trophoblast invasion, and decidualization occurring some 12 hours later ([@B1]).

The ovarian steroid hormones estrogen (E~2~) and progesterone (P4) are the key factors regulating uterine preparation ([@B2]). At ovulation, high levels of E~2~ stimulate uterine cell proliferation ([@B3]). Subsequently, levels of P4 increase, and these suppress cell proliferation and initiate cell differentiation, culminating in the uterus, becoming potentially receptive on the fourth day after mating. On the morning of the fourth day, blastocysts are distributed along the uterine lumen, juxtaposed to the antimesometrial luminal epithelium (LE). Implantation is then initiated by a brief surge of E~2~ (nidatory E~2~) that results in the embryonic trophectoderm invading the LE. The LE adjacent to the invading trophectoderm undergoes either apoptosis or entosis ([@B4]), and the underlying stroma differentiates to form the decidua ([@B5]). Decidualization increases vascular permeability and acts to support early postimplantation embryonic growth and placenta formation, as well as restrict trophoblast invasion.

The hormonal effects on the uterus are mediated either directly or indirectly through locally produced growth factors and cytokines ([@B6]). One of these factors, essential for implantation, is leukemia inhibitory factor (LIF) ([@B7]). During ovulation, LIF is expressed in the murine glandular epithelium (GE) ([@B8]). Over the next 3 days of the reproductive cycle, LIF levels decline but then transiently increase in the GE prior to implantation on D4 of pregnancy. The second increase of LIF is induced by nidatory E~2~, together with the tumor suppressor and transcription factor, p53 ([@B10]). In a wide variety of mammalian species, including human females, a rise in uterine LIF expression is associated with the onset of implantation, implicating LIF in having an important role in regulating uterine receptivity in humans and many other mammals ([@B12]). Polymorphisms in the p53 gene, which are associated with reduced LIF levels due to reduced transcriptional activity, are frequently present among young women undergoing *in vitro* fertilization, potentially correlating a reduction LIF levels with infertility ([@B13]).

Uteri from *Lif*^−/−^ mice show no evidence of epithelial apoptosis, stromal decidualization, or blastocyst invasion ([@B10]). However, transfer of the blastocysts from *Lif*^−/−^ females to wild-type (WT) pseudopregnant recipients results in the embryos undergoing normal implantation and development ([@B7]). Furthermore, a single injection of recombinant LIF into pregnant *Lif*^−/−^ mice on day 4 or 5 of pregnancy induces blastocyst implantation with development to term, revealing that during pregnancy LIF is only required to initiate implantation ([@B10]). The injection of LIF is also sufficient in replacing nidatory E~2~ at inducing implantation in appropriately primed ovariectomized mice. Together these findings demonstrate that E~2~, together with p53, induces LIF expression, with LIF mediating the effects of nidatory E~2~ at initiating uterine receptivity and implantation. In the absence of LIF, implantation fails and is a maternal defect ([@B14]).

LIF acts by binding to the heterodimeric receptor comprised of the LIF receptor (LIFR)*β* and GP130. In the uterus, both LIFR*β* and GP130 are detected in the GE and LE at 3 to 4 days postcoitum (dpc) ([@B15]). LIFR expression is initially restricted to the uterine LE, with levels increasing from day 3 onwards after mating. On day 4 following LIF expression, LIFR levels transiently increase in the LE and to a lesser extent in the GE, thereafter expression declines. GP130 expression is restricted to the apical surface of the day 4 LE ([@B17]). Treatment of the LE with LIF induces activation of the Janus kinase and signal transducer and activator of transcription (Jak/Stat)--signaling pathway that phosphorylates the latent transcription factor Stat3 ([@B15]). Phosphorylated dimers of signal transducer and activator of transcription 3 (pSTAT3) then translocate to the nucleus ([@B18]). In the LE of *Lif*^−/−^ mice, Stat3 translocation to the nucleus does not occur ([@B15]). Mice that are homozygous for a deletion of the Stat3-GP130 docking site show defective implantation, and deregulation of soluble GP130 has been reported in patients with unexplained fertility ([@B19]). In addition, genetic ablation of the *Stat3* gene or the application of Jak/Stat inhibitors ([@B21]) results in defective implantation.

A deeper examination into the role of LIF signaling components in implantation is complicated due to the broad expression of these proteins, with the loss of each of the three proteins (LIFR, gp130, and Stat3) resulting in embryonic/perinatal lethality ([@B24]). *Lifr*-deficient mice die during embryogenesis or shortly after birth making it impossible to determine the LIFR's role at regulating implantation. To define this role, we first derived a mouse line carrying conditional alleles of *Lifr* (*Lifr^flx/flx^*) by the introduction of LoxP sites at the 5′ and 3′ ends, flanking the extracellular domain of the *Lifr* gene. In addition, we established a mouse line (*Ltf^Cre/Cre^*) in which the lactotransferrin/lactoferrin gene (*Ltf*) was used to drive *Cre* recombinase expression in the uterine epithelia. Lactotransferrin is an iron-binding antimicrobial protein that is expressed in many secretory tissues including tear ducts, salivary glands, and mammary glands, as well as the uterine GE and LE, where it functions as part of the innate immune system ([@B27]). Mice lacking a functional *Ltf* gene are viable and overtly normal. In the murine GE and LE, *Ltf* expression is induced by E~2~ and inhibited by P4 and is highly expressed for 3 days after ovulation. The Cre recombinase gene was "knocked into" the *Ltf* locus, so placing Cre under the control of the *Ltf* promoter, and we show that this knock-in, in the uterus, restricts Cre expression to the LE and GE.

Here, we show that *Lifr^flx/Δ^* mice crossed with *Ltf^Cre/Cre^* (CB4) mice results in viable adult mice. In the females, there is a loss of the *Lifr* expression in the uterine LE and GE. This is associated with a failure to activate the Jak-Stat pathway upon treatment, with LIF resulting in the majority of blastocysts not implanting.

Materials and Methods {#s1}
=====================

Mice {#s2}
----

Mice were maintained at the A\*STAR Biological Resource Centre facility in accordance with ([@B28]), with the protocols reviewed and approved by the A\*STAR Biological Resource Centre Institutional Animal Care and Use Committee.

Derivation of the Ltf-Cre and Lifr^flx/flx^ lines {#s3}
-------------------------------------------------

An outline of the three transgenic and recombinant (gene-targeted) lines is presented in Supplemental Fig. 1.

Transgenic Ltf-Cre mice {#s4}
-----------------------

A 2.5-kb *Eco*RI-*Sma*I fragment from the mL14p9E plasmid containing the *Ltf* promoter (corresponding to bases --2637 to --18, ATG = 1) was ligated with the Cre-poly (A) cassette, to generate a *Ltf*-Cre transgenic mouse line by pronuclear injection of the plasmid (Supplemental Figs. 1A and 2A).

Ltf-Cre (L4-Cre) transgenic animals were generated by standard pronuclear injection techniques at the National Cancer Institute at Frederick transgenic mouse facility. After pronuclear injection of the transgene, 170 mice were derived and genotyped by southern blotting to detect the presence and dosage of the transgene. Six males from the 55 genotyped as being positive for the transgene were then subsequently analyzed, by crossing with Rosa26R3 female reporter mice ([@B29]). From each female, the E13 embryo was collected and stained for *β*-galactosidase expression.

Ltf-Cre (CB4) {#s5}
-------------

To derive the "knock-in" mouse line, CB4, the *Cre* recombinase, was inserted into the endogenous lactoferrin gene, just downstream of the ATG start site (Supplemental Fig. 1B and Supplemental Fig. 3). The lactoferrin (*Ltf*) gene consists of 17 exons and is transcribed as a single transcript. A 9-kb *Eco*RI fragment in pGEM3Z (mL14p9E) containing 2.6 kb of 5′ flanking sequence and the first eight exons of the *Ltf* gene, was subcloned from a 14-kb *Ltfl* phage clone (mL14 from a 129/J mouse genomic DNA library, DASH, Strategene---a gift of C. T. Teng; Supplemental Fig. 3A and 3B). An *Xba*I fragment containing exon 1 was subcloned into pBluescript. Cre recombinase complementary DNA (cDNA) containing the SV40 poly (A) sequence was excised from the pmnCre plasmid (gift from P. Soriano) using *Sty*I*-Hin*dIII digestion and cloned by blunt-end ligation into the *Sty*I site at bp72 in exon 1. The resulting *Xba*I sequence containing Cre-pA was then recloned into mL14pE9. A neomycin (neo) cassette under the control of the PGK promoter was isolated from pPGKneobpA, using *Xho*1, was blunt-end ligated into the partially digested *Xba*I site. A thymidine kinase (TK) cassette, under the control of the MC1 promoter from pKS-TK, was cloned into the *Xho*1*-Bam*H1 (in the vector) site to replace an *Xho*1*-Eco*RI fragment in the mL14p9E plasmid, thus generating the targeting vector, pLF-C-*N*-TK (Supplemental Fig. 3B). A 1.5-kb fragment spanning exons 5 to 8 was excised with *Xho*1*-Bam*H1 (Supplemental Fig. 3B) and used as a probe for southern analysis to detect homologous recombinants (Supplemental Fig. 3D). The resulting transcript from the targeted allele (Supplemental Fig. 3B) would produce the initial 17 amino acids of *Ltf* followed by the Cre sequence (Supplemental Fig. 3C and 3E).

Derivation of the a conditional LifR^flx/flx^ allele {#s6}
----------------------------------------------------

The *LifR* gene contains 21 exons spanning some 50 kb. To generate the conditional *LifR* allele (*LifR^flx/flx^*; Supplemental Fig. 1C), two targeting vectors were constructed: pTV-LRup (pTV-LifR-fH), which generated (LifRflx/flxHyg), and pTV-LRdown (pTV-LifR-fN), which generated LifRflxlxNeo (Supplemental Fig. 4A and 4B). These vectors targeted introns 1 and 14, respectively ([@B30]). pTV-LRup was derived from pl5-5.5 Asp, a 5.7-kb *Kpn*I fragment between exons 1 and 2 and cloned into pGEM7 (gift from C. Ware) ([@B25]). A PGK-hygro-poly (A) cassette flanked by loxP sites was blunt-end ligated into the *Bst*EII site. The resulting construct was digested with *Bam*HI and cloned into pBS-TK, containing the TK negative selection cassette. The 0.5-kb *Bam*HI*-Xba*I fragment in p15-5.5, absent from pTV-LRup, was used as a probe for southern analysis.

The genomic DNA fragment used to make the targeting vector pTV-LRdown (pTV-LifR-fH) was derived by screening a library of 129 bacterial artificial chromosomes (BACs; RP22-129S6/SvEvTac Research Genetics) using LifR cDNA as a probe. From 27 BAC clones, three were confirmed by dot blot analysis as containing the LifR gene (RP22-175O16, RP22-417F23, and RP23-476A13). DNA from a mixture of the three BACs was digested with *Eco*RI; large fragments were gel purified and cloned into the *Eco*RI site of pGEMTEasy (Promega). Clones were screened by polymerase chain reaction (PCR) using primers targeting the fibronectin type III domains of LifR (exons 12 to 14), LR1783 forward (5′-CATTGAACGAGGAGACACAGTCAGTTTTGG-3′) and LR2197 reverse (5′-GAACGTAACAGTTGGTATCCCTGGTTAGTGC-3′), resulting in the identification of a 9kb *Eco*RI fragment containing exons 11 to 16. A PGKneobpA cassette flanked by loxP sites was excised from pHR68 (gift from D. Duboule) by *Xho*I digestion and inserted into an *Xho*I site within intron 14 in the same orientation as the PGK-hygro-poly (A) cassette. An MC1-TK cassette was cloned into the *Sac*1*-Sal*1 site to generate the pTV-LRdown targeting vector. The DNA fragment used for southern analysis was generated from the BAC by cloning an *Eco*R1*-Bam*H1 fragment 3′ to the targeting construct.

Gene targeting in embryonic stem cells {#s7}
--------------------------------------

The targeting vectors were linearized by *Not*1 digestion and electroporated into W9.5 129 embryonic stem (ES) cells. ES clones were cultured and selected for as described ([@B31]). For the *LtfCre* (CB4) knock-in southern analysis, genomic DNA was digested with *Eco*R1. The blots were probed with a 1.0-kb *Xho-Bam*1 fragment from mL14p9E corresponding to the sequence immediately 3′ to the targeting vector. The probe hybridized to the 9-kb WT allele and a 7.4-kb recombinant allele due to addition of *Eco*R1 site within the neo cassette (Supplemental Fig. 2B). Four positive clones were identified among 144 G418-resistant clones. Clones were karyotyped to ensure diploidy, and two clones were expanded, injected into C57Bl/6 blastocysts, and transferred to B6CBAF1 recipient females. Germline chimeras were identified and transmission of the *LtfCre* verified by PCR ([@B31]).

For derivation of the LifR^flx/flx^ conditional mouse line, a double targeting strategy was used. Initially, the constructs pTV-LRup and and pTV-LRdown were electroporated individually to test their respective targeting efficiencies. Screening of 48 antibiotic-resistant clones using *Kpn1* digestion for LRup (LifRflxH), which produced a 5.7-kb WT band, or a 4.1-kb mutant band and *Bam*H1 digestion for LRdown (LifRflxH) that resulted a 3.9-kb WT band or a 5.1-kb recombinant band, was performed. The LRup (LifRflxH) electroporation produced 32 (67%) positive clones, whereas the LRdown (LifRflxNeo) electroporation produced 22 (46%) positive clones. The high rate of homologous recombination revealed that the *LifR* locus is easily targetable and that a simultaneous double-targeting strategy could be attempted. To this end, the ES cells were electroporated with a mixture containing both the pTV-LRup and pTV-LRdown targeting constructs. After 24 hours, ES cells were simultaneously selected with hygromycin (Invitrogen, Carlsbad, CA) and G418 (Invitrogen). Of 48 clones, five were confirmed to be positive by southern analysis for homologous recombination at both loci. To further ensure that both targeting vectors recombined with the *LifR* gene *in cis* and ensure that the loxP sites were functional, Cre recombinase was transiently expressed in the five ES clones by transfection of pMC1-Cre (a Cre cDNA expressed under the MC1 promoter, gift of K. Rajewsky). PCR was used to identify the deletion product of the floxed *LifR*. Two of five clones were injected into blastocysts to generate chimeras. Clone J8 produced germline offspring inheriting the conditional *LifR^flx/+^* allele.

Maintenance and genotyping of mice {#s8}
----------------------------------

Germline transmission of the *Ltf-Cre* knock-in was confirmed by southern analysis, and mice were subsequently genotyped by PCR amplification of genomic DNA. Two pairs of PCR primers were used to genotype LtfCre (CB4) lines: Cre primers (Cre73 forward: 5′-GTGTCCAATTTACTGACCGTACACC-3′; Cre373 reverse: 5′-GACGATGAAGCATGTTTAGCTGG-3′) and Ltf primers (forward 5′-TGAGGTCACCCAGCACAGATAAAG-3′; Ltf intron1-5′-GAGAGGGTGAGATGTTCCTGTGAGTC), corresponding to sequences within the promoter through intron 1. The Ltf primers generate a 331-bp WT product or a 1.7-kb LtfCre (CB4; CreKI) product.

Mice containing the *LifR^+/flx^* alleles were identified by PCR using the following primers: LifR-CKO up-forward (U5) 5′-CCTTTTGCAGTCTCACAGGTCTTG-3′; Lifr-CKO up-reverse (U3) 5′-TGGAAAGCAGAGAAGCACAAGC-3′ to generate a 368-nucleotide (nt) WT product, a ∼2-kb hygromycin-containing fragment (Hygro-on; fH) or a 461-nt loxP-containing product (Hygro-off; fDH). Lifr-CKO down-forward (D5) 5′-gcccctttgtgacatactcgattc-3′; Lifr-CKO down-reverse (D3) 5′-TGGTAAGTCCAACTCAGCTAAGTGC-3′ to generate a 172-nt WT product, an ∼2-kb neo-containing fragment (fN) or a 272-nt loxP-containing fragment. In addition, using primers U5 together with D3, amplifies a 474-nt product in the null *Lifr^Δ/Δ^* allele.

To delete the neo and hygromycin selectable markers, the *Lifr^fH-fN/fH-fN^* mice were crossed with CB4 mice, and the resultant *Lifr^flx/+:^Ltf^Cre/+^* mice were screened for loss of neo and hygromycin cassettes by PCR as described above. The deletion of the selectable markers leaves two *loxP* sites at introns 1 and 14 intact. To generate the complete *Lifr* deletion (*Lifr^Δ/Δ^*), the *Lifr^flx/flx^* mice were crossed with the *Ltf-Cre* transgenic line (L4-Cre), used here as a general deletor to obtain *Lifr^Δ/+:Cre/+^*. The *Lifr^flx/+^:Ltf ^Cre/+^* mice were then crossed with *Lifr^Δ\ /+^:Cre*-- mice to obtain Lifr^flx/Δ:^:*Ltf ^Cre/+^*. Females with this genotype were then used to determine the consequences of *Lifr* deletion in the LE. To determine the tissue specific expression of Cre activity *in vivo LtfCre/Cre* mice were crossed to the mouse reporter lines: Z/AP ([@B33]), Rosa26R3, and mT/mG ([@B34]).

Histology and immunohistochemistry {#s9}
----------------------------------

For whole-mount embryo analysis, embryos were fixed with 4% paraformaldehyde (PFA). *β*-Galactosidase activity in the Rosa26R3 crosses was detected after incubation with X-gal (5-bromo-4-chloro-3-indolyl-b-[d]{.smallcaps}-galactopyranoside; Invitrogen). Alkaline phosphatase activity in Z/AP mice was detected using BCIP/NBT (5-bromo-4-chloro-3-indolyl phosphate/nitro blue tetrazolium; Vector Laboratories) staining according to manufacturer's protocol. Cre expression in the uterus was evaluated using the Gt (ROSA)26R3*^Sortm1Sor/J^*, Z/AP, and mT/mG mouse reporter lines. Frozen sections were fixed with 4% PFA and then stained with BCIP/NBT or by immunofluorescent analysis for mT or mG. Immunofluorescence analysis was performed on paraffin-embedded samples as previously described ([@B17]).

The effects of *Lifr* deficiency on glial cells of the central nervous system (CNS) and osteoclasts in bone were histologically characterized and by hematoxylin and eosin (H&E) staining with images being recorded on a Zeiss Axioimager. Paraffin-embedded thin sections of spinal cords (5 μm) were stained with an antibody against GFAP to identify glial cells and counterstained with Nissl stain. The osteoclasts in the long bones were identified by their unique morphology and size after H&E staining, performed using standard histological procedures.

Analysis of the CB4 mT/mEGFP reporter mice {#s10}
------------------------------------------

The uteri from day 1 pregnant CB4^+/+^/TL ^+/+^ or Tl ^+/+^ mice were fixed in 4% PFA (Thermo Scientific, Rockford, IL) in phosphate-buffered saline (PBS) pH 7.4 for 24 hours, followed by fixation in 30% sucrose (Sigma, St Louis, MO) in PBS pH 7.4 for 24 hours at 4°C. Fixed uteri were cut into pieces and placed in tissue freezing medium (Electron Microscopy Sciences, Hatfield, PA) and frozen in cold heptane (Sigma) kept on dry ice. Cryosections of 10 μm were cut and stored at --70°C. For detecting membrane-targeted green fluorescent protein (mGFP) fluorescence, cryosections were dried completely at room temperature for 10 to 15 minutes. The sections were treated with chloroform: isoamyl acetate 24:1 (Sigma) for 10 seconds to eliminate background autofluorescence. The sections were dried and then rehydrated in PBS, pH 7.4, for 15 minutes. Sections were incubated in 1% sodium borohydride (Sigma) in PBS, pH 7.4, for 20 minutes followed by washing in PBS twice for 5 minutes each. The sections were treated with a mouse-on-mouse blocking reagent (Vector Laboratories, Burlingame, CA) for 1 hour and then washed in PBS twice for 5 minutes each to quench additional autofluorescence arising from antibody binding to blood vessels. The sections were incubated with DAPI (Invitrogen) to stain nuclei for 10 minutes and washed with PBS. Subsequently they were treated with 75 mM copper sulfate in ammonium acetate solution, pH 5.0 (Sigma), for 90 minutes to further decrease lipofuscin autofluorescence ([@B35]). The sections were washed in PBS and mounted in ProLong gold antifade mounting medium (Invitrogen) and viewed and photographed using a Zeiss LSM510 confocal microscope (Carl Zeiss, Jena, Germany).

Implantation analysis {#s11}
---------------------

For the analysis of blastocyst implantation, female mice with the desired genotype (*Lifr^flx/Δ:^ Ltf^Cre/+^*) were derived and were mated with WT males of proven fertility. Plug dates were recorded. After the mice were plugged at least three times without becoming pregnant, they were killed after the fourth mating at 7 dpc. Uteri were collected and flushed to recover unimplanted blastocysts, and these were transferred to pseudopregnant recipients ([@B7]).

Northern analysis {#s12}
-----------------

From a pool of three to five uteri, 10 µg of total RNA was prepared, according to the manufacturer's instructions (Northern Max, Ambion), separated by electrophoresis in formaldehyde denaturing gels, and transferred onto Hybond-N+ membrane (Amersham). P-32--labeled cDNAs corresponding to Cre and lactoferrin were used as probes. After standard washing, the membranes were analyzed using a phosphorimager for 1 to 3 days.

*In situ* hybridization of uterine sections {#s13}
-------------------------------------------

Uteri were isolated and frozen in optimum cutting temperature and then sectioned at 10 µm and mounted on Superfrost slides (VWR International). *In situ* hybridization was performed as previously described ([@B9]). Sections were warmed to room temperature and fixed in 4% PFA. Sections were treated with Proteinase K and prehybridized in 50% (volume-to-volume ratio) formamide, 4×SSC, 5% dextran sulfate (weight-to-volume ration), 1× Denhardt's solution, 0.25 mg/mL transfer RNA and heat-denatured salmon sperm DNA (0.5 mg/mL) for 3 hours at 42°C. A full-length Lifr cDNA clone was used to generate sense and antisense probes by *in vitro* transcription with (*α*-35S) uridine triphosphate. The hybridization was performed overnight with either S35-labeled sense or antisense probes. Slides were processed for liquid emulsion autoradiography and visualized using Kodak D-19 developer.

LIF treatment and Western analysis {#s14}
----------------------------------

LE from D3 pregnant mice was isolated from uteri by enzymatic digestion as previously described ([@B15]). The purified LE was incubated at room temperature in freezing holding buffer (Specialty Media). LIF (Esgro, Millipore) was added and incubated for 2 hours. Proteins were extracted by lysis buffer containing 0.1% NP-40, 50 mM Tris-HCl, pH 7.5, 150 mM NaCl, and complete miniprotease inhibitor cocktail (Roche). Protein extracts were separated on 12% acrylamide/bisacrylamide gels and transferred to polyvinylidene difluoride membranes (Bio-Rad). Membranes were blocked in 5% nonfat dry milk in TTBS (0.1% Tween 20 in Tris-buffered saline) and incubated O/N with the following primary antibodies: pSTAT3 (Cell Signaling) and STAT3 (Cell Signaling) at 4°C. Loading was normalized using an antibody to glyceraldehyde 3-phosphate dehydrogenase. After washing in TTBS, membranes were exposed to horseradish peroxidase--conjugated secondary antibodies, incubated in enhanced chemiluminescence solution (Amersham), and processed for autoradiography on film (Kodak).

Results {#s15}
=======

Transgenic lactoferrin-directed Cre mice do not show Cre restriction to the LE {#s16}
------------------------------------------------------------------------------

In the sexually mature uterine LE, lactoferrin (lactotransferrin, *Ltf*) is induced by E~2~, both during estrous and the first 3 days following ovulation. Its expression is then inhibited by a rise in P4 ([@B27]). To determine whether lactoferrin would be a tissue-specific promoter for Cre expression in the uterine LE, we initially generated a transgenic line, *Ltf*-Cre (Supplemental Fig. 1A) using an *Eco*RI*-Sma*1 fragment from the *Ltf* promoter (corresponding to sequences --2637 to --18; transcriptional start site = +1) that contains the E~2~-regulated element. Following pronuclear injection, we examined the offspring from six independently derived transgenic males. The offspring from all six males, when crossed to mice carrying the *β*-galactosidase (ROSA26R3*^Sortm1Sor/J^*) reporter gene, all showed ubiquitous expression of *β*-galactosidase in midgestation embryos (Supplemental Fig. 2A), indicating that the *Ltf*-Cre transgene was probably expressed very early in development. We retained one line, homozygous for the transgene, which subsequently served as a universal constitutive deleter line to generate the *Lifr^Δ/Δ^* mice.

Insertion of Cre recombinase into the endogenous Ltf gene results in restricted Cre expression {#s17}
----------------------------------------------------------------------------------------------

Because the transgenic approach failed to produce mice with *Cre* expression restricted to the LE and GE, we then chose to "knock-in" the *Cre* recombinase gene into the *Ltf* gene so that *Cre* is under control of all *Ltf* regulatory elements. The vector for a knock-in of *Cre* recombinase was made by inserting a modified *Cre* recombinase cDNA (mnCre) within exon 1, downstream of the ATG start site of the *Ltf* gene (Supplemental Fig. 1 and Supplemental Fig. 3A--E).

Four homologous recombinant ES clones (out of 144 clones) were identified and confirmed by southern analysis (Supplemental Fig. 3D). The resulting fusion protein was predicted to contain the initial 14 amino acids of *Ltf* followed by Cre sequence (Supplemental Fig. 3E). Homozygous Cre knock-in (*Ltf^Cre/Cre^* or CB4) mice were indistinguishable from WT siblings and did not display any overt phenotype, consistent with *Ltf*-null mice being viable ([@B39]). There was however some anemia and reduced levels of hemoglobin in pups derived from homozygous mothers (data not shown).

In contrast to the *Ltf-Cre* transgene, the *Ltf-Cre* insertion line (CB4) had a restricted expression profile. Northern blot analysis detected *Cre* recombinase transcripts and no *Ltf* transcripts in the uteri from homozygous *CB4* mice (Supplemental Fig. 2B). To further evaluate the tissue-specific expression and activity, female CB4 mice were crossed with different reporter lines; the double-fluorescent mT/mG reporter Line ([@B34]), the *β*-galactosidase reporter mice Gt (ROSA26*^Sortm1Sor/J^*) ([@B29]) and the alkaline phosphatase Z/AP ([@B33]). As shown in Supplemental Fig. 2C, E13 embryos generated from the Z/AP × *CB4* cross, in contrast to the transgenic lines, did not show ubiquitous AP expression, but showed small discreet regions of AP expression that varied between individual embryos. CB4 female mice were then crossed with the dual reporter mT/mG male reporter mice to obtain a more precise definition of Cre activity in the different tissues, and specifically in the uterus of CB4 × mT/mG female offspring. The mT/mG mice constitutively express Tomato Red (mT) prior to Cre-mediated recombination. Following Cre introduction, expression of mT is lost and expression is switched to an mGFP, specifically in cells where *Cre* is functional. Strong mT expression was observed in the uterine stroma without CB4 \[[Fig. 1(B)](#F1){ref-type="fig"} and [1(D)](#F1){ref-type="fig"}\]. After crossing with CB4 males, mG expression was only induced and localized at the LE membrane and more weakly in the GE membranes, as well as a few cells in the stroma that were probably neutrophils or macrophages expressing *Ltf* \[[Fig. 1](#F1){ref-type="fig"}(E) and (H)\] ([@B37]). For unknown reasons, mT expression in the stroma was lost, but no mG expression was induced. In females prior to their first reproductive cycle (at ∼5 to 6 weeks) or in ovariectomized mice, mG expression was not induced in the LE or GE. However, following E~2~ injection (50 ng), mG was induced in the LE of ovariectomized mice (data not shown). Confirmation that Cre activity in the CB4 line was restricted to the uterine LE and GE was established by crossing the Cre mice to the *β*-galactosidase reporter mice Gt (ROSA26*^Sortm1Sor^*/^J^) where *β*-galactosidase activity was restricted to the LE and GE \[[Fig. 1(I)](#F1){ref-type="fig"} and [1(J)](#F1){ref-type="fig"}\]. In other tissues from the mT/mG × CB4 mice, strong Cre activity was noted in the salivary glands, whereas in the liver (where the LIFR is highly expressed), no activity was detected. Weak activity was, however, detected in the ovarian stroma and, to a lesser extent, the heart myocardium, with no activity being detected in other adult tissues (Supplemental Fig. 5).

![Cre reporter expression in CB4 × mT/mG mice is restricted to the uterine luminal and glandular epithelium. (A--D) Expression of mT of mT/mG mice is localized to the stromal and epithelial cells in uterus: (A) Control, no antibody; (B) tomato red; (C) 4′,6-diamidino-2-phenylindole; (D) merged. (E--H) Lactotransferrin-driven Cre (CB4) ablates mT expression in the LE and GE and induces mGFP specifically in the LE and GE. (E) mEGP; (F) mT; (G) 4′,6-diamidino-2-phenylindole; (H) merged. The reason that mT expression is lost in the stroma is unclear; however, mGFP is clearly restricted to the LE. Scale bar: 50 μm. (I and J) CB4 Cre induces *β*-galactosidase expression in the uterine GE and LE (I) *β*-gal^+/+^ expression in the absence of CB4; (J) CB4 × *β*-gal^+/+^.](en.2017-00103f1){#F1}

Derivation Lifr^flx/flx^ conditional allele {#s18}
-------------------------------------------

To ensure that as much of the *Lifr* gene could be deleted following recombination, *loxP* sites were introduced into *Lifr* gene flanking the exons encoding the extracellular domains the LIFR (Supplemental Fig. 4A--F). Mice homozygous for the floxed *Lifr* (*Lifr^flx/flx^*) allele and mice heterozygous with a deleted allele (*Lifr^Δ/+^*or *Lifr^Δ/flx^*) were viable and indistinguishable both in growth rate and fertility from their WT siblings.

We derived homozygous deleted *Lifr^Δ/Δ^* mice by crossing the *Lifr^flx/flx^* mice with the *Ltf*-Cre constitutive deleter line and compared their phenotype to the phenotype of the previously described *Lifr^−/−^* mice ([@B25]). The *Lifr^−/−^* mice die perinataly, and viable *Lifr^Δ/Δ^* offspring were identified at birth which then subsequently died within a few hours after birth (n = 38 newborns analyzed; *P* \> 0.001). *Lifr^Δ/Δ^* E16 and E19 embryos were identified (n = 7) at normal Mendelian ratios and showed no overt abnormalities apart from being smaller. Compared with WT littermates, *Lifr^Δ/Δ^* mice were 8% (E14) and 27% (E19) lighter and 5% (E14) and 12% (E19) shorter in body length (data not shown). Such growth retardation may have been due defective placental development, as reported for the *Lifr^−/−^* mice ([@B25]), because the placenta expresses high levels of the LIFR. *Lifr^−/−^* mice have increased osteoclast numbers in the long bones and defects in glial cell differentiation in the CNS. We observed a similar reduction in glial cell numbers, by GFAP staining in both E16 and E19 *Lifr^Δ/Δ^* embryos (Supplemental Fig. 6A). We also observed increased osteoclast numbers in the long bones, visualized by H&E staining (Supplemental Fig. 6B). Because of the perinatal lethality of the *Lifr^Δ/Δ^* mice, the mice were maintained with a *Lifr^flx/flx^* genotype.

Loss of Lifr in the LE of Lifr^flx/flx^: Ltf^Cre/Cre^ mice results in infertility {#s19}
---------------------------------------------------------------------------------

We derived *Lifr^flx/Δ^:Ltf^Cre/+^* females to determine if LE/GE expression of the LIFR is required for implantation. Mice with either of these genotypes were, in size and overall health, indistinguishable from WT siblings, indicating that any non LE-GE expression of *Ltf^Cre/Cre^* did not significantly delete *Lifr^flx/flx^* in other adult tissues, such as the liver, where the LIFR is highly expressed ([@B40]) or during development, which would result in potential lethality.

To analyze the consequences of *Lifr* loss in the LE on blastocyst implantation, females with the desired genotype (*Lifr^flx/Δ^:Ltf^Cre/+^*) were mated with WT males of proven fertility. Plug dates were recorded from a total of 11 females. After each of the females had mated for at least three cycles without becoming pregnant, a fourth mating was initiated. The females were then killed at 7 days after the last mating (7 dpc). Uteri were collected, examined for the presence of implantation sites and then flushed to isolate unimplanted blastocysts. From the 11 females, 27 hatched, unimplanted blastocysts were recovered from six of seven mice that showed no indication of implantation sites \[[Fig. 2](#F2){ref-type="fig"}(A)\], indicating their uteri did not support implantation. The remaining four females showed evidence of implantation with a total of seven decidual swellings being identified in the four mice. The recovered blastocysts \[[Fig. 2](#F2){ref-type="fig"}(B)\] were morphologically similar to normal blastocysts undergoing implantational delay, in that they were elongated and were not enclosed in a zona. To verify that the embryos were unaffected by loss of *Lifr* expression, the blastocysts were transferred to WT pseudopregnant recipients. Twelve blastocysts were transferred to pseudopregnant WT recipients, and seven pups were subsequently born. These data indicate that implantation failure in *Lifr ^flx/Δ^:Ltf^Cre^*^+^ LE mice is a consequence of a defective uterus rather than defective blastocysts. The uteri from which the blastocysts were recovered showed no evidence of a decidual response or any indication that implantation had been initiated (data not shown).

![Unimplanted blastocysts isolated from the uteri of *Lifr^flx/Δ^:Ltf^Cre/+^* mice. Upper panel: *Lifr^flx/Δ^:Ltf^Cre/+^* uterus at 7 dpc showing no evidence of embryo implantation. Lower panel: Unimplanted blastocysts flushed from the uteri of a *Lifr^flx/Δ^:Ltf^Cre/+^* female at day 7 after mating with a fertile male. The blastocysts are not enclosed by a zona pellucida and are morphologically typical for blastocysts undergoing implantational delay.](en.2017-00103f2){#F2}

The fact that seven implantation sites were detected in four of the *Lifr ^flx/Δ^:Ltf^Cre^*^+^ females, even after four rounds of mating, indicated that *Ltf-Cre* mediated deletion, may, occasionally not be fully penetrant. To analyze this, we preformed *in situ* hybridization and Immunostaining on uterine sections from the females. *In situ* hybridization, using a full-length *Lifr* cDNA as a probe, hybridized to *Lifr* transcripts in the LE of the WT uterus. The *Lifr* hybridization signal in the LE was weak on day 3 dpc, and increased in intensity between days 4 and 5 dpc, in agreement with previous reports ([@B16]) \[[Fig. 3(A)](#F3){ref-type="fig"}, panel b\]. No signal was detected using the sense probe. Screening for the *Lifr* in *Lifr^flx/Δ^:Ltf^Cre/+^*mice revealed the complete absence of *Lifr* transcripts from three *Lifr ^flx/Δ^:Ltf^Cre^*^+^ individuals \[[Fig. 3(A)](#F3){ref-type="fig"}, panels c and d\]. However, a substantial hybridization signal, indicative of *Lifr* transcripts, was found in the LE of the fourth mouse (not shown). These results were supported by western analysis and immunostaining of the LIFR protein \[[Fig. 3(B)](#F3){ref-type="fig"}, panels e--h, and [3(C)](#F3){ref-type="fig"}\] where LIFR was detectable in the basal and apical sides of the LE of WT mice 2 hours after an injection of nidatory E~2~ \[[Fig. 3(B)](#F3){ref-type="fig"}, panel e\], whereas in the LE from three *Lifr*^−/−^, it was either undetectable by immunostaining or western analysis in two individuals \[[Fig. 3(B)](#F3){ref-type="fig"}, panels f and h, and [3(C)](#F3){ref-type="fig"}\] and weakly expressed in the LE of another mouse \[[Fig. 3(B)](#F3){ref-type="fig"}, panel g\].

![Loss of LIFR expression in the uteri of *Lifr^flx/Δ^:Ltf^Cre/+^* mice is associated with a failure to phosphorylate STAT3 in the luminal epithelium. (A) *Lifr* transcripts (by *in situ* hybridization) are absent in the LE in the *Lifr^flx/Δ^:Ltf^Cre/+^* uteri on day 4 of gestation (panel a: WT bright field; panel b: WT dark field showing hybridization to the LE; panel c: *Lifr^flx/Δ^:Ltf^Cre/+^* bright field; panel d: *Lifr^flx/Δ^:Ltf^Cre/+^* dark field showing loss of the hybridization signal). (B) Immunostaining of LIFR expression in the LE shows loss of the LIFR in two ovariectomized mated *Lifr^flx/Δ^:Ltf^Cre/+^* females 2 hours after E~2~ injection on day 4 after mating compared with WT controls (panel e: WT; panel f: D4 cLIFR^−/−^ 1; panel g: D4 cLIFR^−/−^ 2; panel h: day 7 cLIFR^−/−^; panel i: negative control). (C) Western analysis showing of LIFR and STAT3 in the LE. Isolated LE from *Lifr^flx/Δ^:Ltf^Cre/+^* and WT mice day 4, 2 hours after E~2~ injection at 4 dpc; also shows loss of the two LIFR proteins and absence of pSTAT3 in the LE from *Lifr^flx/Δ^:Ltf^Cre/+^* mice. CyclinD was used as a loading control. (D) Stat3 expression is reduced in the LE of *Lifr^flx/Δ^:Ltf^Cre/+^* mice. There is no nuclear localization of STAT3 in the LE of ovariectomized *Lifr^flx/Δ^:Ltf^Cre/+^* 4-dpc females 2 hours after E~2~ injection compared with WT (panel j: WT with strong STAT3 expression in the LE and GE; panel k: D4 cLIFR^−/−^; panel l: D7 cLIFR^−/−^ 2; panel m: negative control). (E) Nuclear localization of pSTAT3 is absent in the LE of ovariectomized pregnant *Lifr^flx/Δ^:Ltf^Cre/+^* females. Two hours after E~2~ injection at 4 dpc, WT LE shows pSTAT3 nuclear localization (panel n: WT showing strong nuclear localization; panel o: D4 cLIFR^−/−^ 1; panel p: D7 cLIFR^−/−^ 2; panel q: negative control). (F) Western analysis of STAT3 and pSTAT3 levels on extracts from the LE of WT and *Lifr^flx/Δ^:Ltf^Cre/+^* mice on days 3 and 4 following LIF treatment of isolated LE. In the left panel (D3), there is robust expression of STAT3 in both treated and untreated WT LE (lanes 1 and 2). Following LIF treatment, pSTAT3 levels are increased (lanes 3 and 4). On the right, pSTAT3 levels in the *Lifr^flx/Δ^:Ltf^Cre/+^* LE from day-4 uteri are reduced and do not increase following LIF treatment (lanes 5--8), as seen in WT LE (lanes 9 and 10). Glyceraldehyde 3-phosphate dehydrogenase was used as a loading control. Scale bars: 50 μm.](en.2017-00103f3){#F3}

There was an apparent correlation between fertility (ability to support implantation) and detectable *Lifr* mRNA signal in the LE; the pregnant female was still LIFR positive, whereas the infertile ones showed no LIFR signal. These results indicate that Cre recombinase, under the control of the *Ltf* promoter in *Lifr^flx/Δ^:Ltf^Cre/+^* females, was effective in the tissue-specific ablation of the *Lifr* in the majority of mice analyzed.

STAT3 activation by LIF is inhibited in the Lifr^flx/Δ:^LtfCre+ LE {#s20}
------------------------------------------------------------------

The binding of LIF to the LIFR/gp130 receptor complex activates the JAK/STAT pathway ([@B41]). Previously, we demonstrated that STAT3 is constitutively expressed in the LE during the preimplantation period but is only phosphorylated and translocates to the nuclei in the LE, but not the GE, in response to LIF treatment on days 3 and 4 after mating ([@B15]). To determine whether STAT3 is phosphorylated in the LE of *Lifr^flx/Δ^:Ltf^Cre/+^* mice, we performed western and immunofluorescence analysis on whole uteri and LE extracts from mice on days 3 and 4 after mating \[[Fig. 3](#F3){ref-type="fig"}(D--F)\]. We isolated and purified LE from WT females at 3 dpc and incubated the LE with LIF as previously described ([@B15]). Treatment of the WT LE, with LIF, resulted in a robust increase of phosphorylated Stat3 \[[Fig. 3(F)](#F3){ref-type="fig"}, lanes 1--4\]. As with previous observations, the overall levels of STAT3 did not change in response to LIF treatment, but pSTAT3 levels were strongly increased \[[Fig. 3(F)](#F3){ref-type="fig"}, lane 4\] ([@B15]). Extracts of LE from WT and *Lifr^flx/Δ^:Ltf^Cre/+^*mice from 4 dpc were analyzed following LIF treatment using an antibody specific for pSTAT3. Although treatment of WT LE with LIF resulted in STAT3 phosphorylation ([Fig. 3](#F3){ref-type="fig"}, lanes 9 and 10), in the *Lifr^flx/Δ^:Ltf^Cre/+^*, LE extracts STAT3 phosphorylation did not change \[[Fig. 3(F)](#F3){ref-type="fig"}, lanes 5--8\].

These results were confirmed by Immunostaining uteri from ovariectomized WT and *Lifr^flx/Δ^:Ltf^Cre/+^* mice 2 hours after the injection of nidatory E~2~ (n = 3 each genotype). STAT3 protein was detected in the cytoplasm of WT and *Lifr^flx/Δ^:Ltf^Cre/+^* LE at varying levels \[[Fig. 3(D)](#F3){ref-type="fig"}, panels j--m\]; however, only in the WT LE was pSTAT3 localization to the nuclei detected \[[Fig. 3(E)](#F3){ref-type="fig"}, panel n\]---not in the LE nuclei from the *Lifr^flx/Δ^:Ltf^Cre/+^* mice \[[Fig. 3(E)](#F3){ref-type="fig"}, panels o--q\].

MSX1 uterine expression persists in the Lifr^flx/Δ^:Ltf^Cre/+^ LE {#s21}
-----------------------------------------------------------------

One of the genes whose expression is inhibited in the LE by LIF is the homeobox gene *Msx1* ([@B17]). In WT mice on day 4 dpc, MSX1 expression is detectable in the uterine LE ([@B42]). However, within 2 to 3 hours after either E~2~ or LIF injection, MSX1 expression is completely suppressed \[[Fig. 4](#F4){ref-type="fig"}(A)\]. In the *Lifr^flx/Δ^:Ltf^Cre/+^* uteri, MSX1 expression was sustained and even appeared to have spread into some stromal cell nuclei \[[Fig. 4](#F4){ref-type="fig"}(B)\] by 3 hours after E~2~ injection. This supports previous findings that LIF induction on day 4 suppresses MSX1 expression and that this suppression is necessary to render the uterus receptive to implanting blastocysts.

![MSX1 expression is disrupted in the uteri of *Lifr^flx/Δ^:Ltf^Cre/+^* mice after E~2~ induction. (A) Two hours after E~2~ injection at 4 dpc, MSX1 expression has disappeared from the WT uterus. (B) In the uteri of *Lifr^flx/Δ^:Ltf^Cre/+^* mice, MSX1 expression persists in the LE and has extended in stromal cells. (C) Negative control.](en.2017-00103f4){#F4}

Discussion {#s22}
==========

Embryo implantation is a highly complex yet coordinated process that is driven by the ovarian steroid hormones E~2~ and P4. These hormones operate by activation of many autocrine and paracrine signaling molecules in different tissue compartments of the uterus. Among these signaling molecules, the cytokine LIF is essential. LIF's action on the LE results in the change in the expression of at least 50 transcription factors within 1 hour of LIF treatment. These transcription factors, in turn, activate a multitude of physiological pathways ([@B17]). Analysis of how these different factors act in concert, resulting in successful blastocyst implantation, has been hampered by the lack of an appropriate *in vitro* system to dissect the molecular and cellular events. Consequently, it has been necessary to resort to studying the process *in vivo*, primarily through genetic routes in which mutations are introduced into genes suspected of being important to implantation. However, deletion of many of these genes results in embryonic or developmental abnormalities that prevent female mice from reaching a reproductive maturity. This issue can be sidestepped using the Cre-Lox system to conditionally regulate gene expression.

At least five Cre lines of mice have been derived to specifically delete genes in the uterus, these being *PR*-*Cre* ([@B46]), *Amhr2*-*Cre* ([@B47]), *Wnt7a*-*Cre* ([@B48]), *Sprr2f*-*Cre* ([@B49]), and recently, another *Ltf* line, *Ltf-iCre* ([@B50]). Each of these lines has advantages and disadvantages at directing gene ablation in different cellular compartments. A major issue with many of these lines is that the expression of the genes driving Cre may not be restricted to a specific cell type in the uterus. For instance, PR is expressed in all cellular compartments in the uterus, as well the ovary, mammary gland, and pituitary, so making it difficult to define gene function in uterine biology, if the floxed gene is expressed in additional cell types. Furthermore, some of these genes are expressed, either during embryogenesis or in the maturing postnatal uterus, and so disrupting uterine development rather than physiological function during adult reproduction.

Here, we have described the derivation of an *Ltf-Cre* line (CB4) and showed that it can be used to specifically ablate gene expression in the uterine LE and GE. The mouse line, CB4 (*Ltf^Cre/Cre^*), has Cre recombinase that was inserted into the lactoferrin (*Ltf*) gene, so placing Cre expression under control of the E2/P4 regulated *Ltf* promoter. We used the CB4 line to specifically delete a floxed conditional allele of the LIF receptor in the uterine LE. LIF initiates implantation by binding to the heterodimeric receptor comprised of the LIFR and gp130 proteins that are expressed in the LE. Binding of LIF to the heterodimeric receptor activates the JAK/STAT signaling pathway in the LE ([@B15]), resulting in the LE becoming receptive to the juxtaposed blastocysts. Determining the requirement for the LIFR in implantation has been hindered by the fact that *Lifr*-nulls die at birth, so preventing the analysis of LIFR function in different adult tissues ([@B25]).

In the LE and GE of *Lifr^flx/Δ^:Ltf^Cre/+^* mice, *Lifr* transcripts and protein were eliminated, indicating that the *Ltf--Cre* resulted in deletion the *Lifr^flx/Δ^* alleles. The majority of the *Lifr^flx/Δ^:Ltf^Cre/+^* females, despite repeated mating with males of proven fertility, did not become pregnant or produce offspring. These females were carrying unimplanted blastocysts, and following transfer to pseudopregnant WT recipients, the majority of these blastocysts implanted and developed to term, a result identical to that seen in the *Lif*-null mice ([@B7]). These results demonstrate that LIFR and GP130 expression in the LE, are the signaling receptor components required by LIF to initiate the onset of LE receptivity followed by embryo implantation.

*Lifr* transcript loss in the LE was, in a few mice, incomplete, with some residual *Lifr* signal persisting in about 15% of the LE cells. Such mosaic expression may well account for some *Lifr^flx/Δ^:Ltf^Cre/+^* LE females being subfertile, with a reduced number of implantation sites. Several reasons may account for the apparent partial loss, including insufficient levels of expression of *Cre* from the *Ltf* promoter, *Ltf* expression varying between individual LE cells and the distance between the loxP sites in the floxed *Lifr* allele, reducing the efficiency of recombination. However, the patchy expression of *Cre* activity, both in embryos and in the uterus, as revealed in the reporter mice, suggests that variable expression of Cre is a possibility. These observations suggest that LIFR expression in a few LE cells may be sufficient to allow for the implantation of a few blastocysts, probably in the regions of the LE where LIFR was still expressed, suggesting that changes in the LE in response to LIF that allow embryo implantation are highly localized and do not "spread" to neighboring cells.

Many studies have shown that deletion, mutation, or pharmacological inhibition of either the *Stat3* or the *Gp130* genes results in female infertility and implantation failure. Gp130-null mice die *in utero* due to defective cardiac and vascular development. However, a mouse line homozygous for a truncation of a C-terminal region of gp130, which eliminates the STAT3 binding and activation site, has defective implantation, similar to the LIF-deficient mice ([@B19]). Pharmacological inhibition of the JAK/STAT pathway has also supported the notion that STAT3 and JAK are required for implantation ([@B21]). Recently, the conditional deletion of either *Stat3* or *Gp130* in the uterus using the *Pgr^Cre/+^* was reported ([@B23]). Loss of either factor resulted in female infertility and implantation failure confirming their requirement for implantation, although because *Pgr* is expressed in both the uterine epithelium and stroma, this makes it difficult to interpret which tissue is affected by loss of either factor.

Stimulation of the WT-LE with LIF resulted in efficient phosphorylation of STAT3 and nuclear translocation in the WT LE, but not in LE from the *Lifr^flx/Δ:^Ltf^Cre/+^* mice, where pSTAT3 levels were reduced and did not show increased phosphorylation following LIF treatment. The reduced levels of STAT3 and phosphorylation dynamics may have been partly due to a breakdown in the autoregulation of STAT3 levels due to a failure to increase expression of the negative regulator SOCS3 that inhibits STAT3 phosphorylation and that is transcriptionally induced by pSTAT3. The failure to activate the JAK-STAT pathway in the LE probably was responsible for the persistent expression of the homeobox gene MSX1, in which LIF mediated suppression of MSX1 expression is required for the uterus to become receptive ([@B42]). Together with previous reports, these findings demonstrate the centrality of the LIF-Lifr/gp130-JAK/STAT3 signaling pathway in regulating uterine receptivity and implantation.

Based on our reporter analysis, the CB4 *Ltf-Cre* line was largely effective in expressing Cre recombinase in the LE and in deleting LifR function in this cellular compartment. However, *Ltf-Cre* is strongly expressed in other tissues, especially the salivary gland and more weakly in the heart. Ablation of the *Lifr* in these tissues would probably not affect reproductive functions in the uterus. We also compared the effectiveness of the *Wnt7a*-*Cre* line at deleting the LifR in the uterus and we were only able to derive one female (out of 75 offspring tested) that was of the *Lifr^flx/Δ^*: *Wnt7a ^Cre/+^* genotype, whereas we derived 21 *Lifr^flx/Δ:^Ltf^Cre/+^* females from 81 offspring. This may have been due (based on our observation) to *Wnt7a* --Cre expression in the developing CNS, so ablating LifR that is essential to the developing CNS (data not shown). Cell-specific ablation of any gene of interest in the uterus may therefore require the judicious choice of a specific line of Cre mice.

Although all these results have been obtained primarily in mice, they are relevant to human reproductive health. In women with unexplained fertility defects, altered expression of soluble gp130 has been reported ([@B20]), and reduced fertility is associated with specific polymorphisms in the transcription factor p53 and its regulator Mdm2 affecting the levels of LIF expression in the uterus ([@B23]). In summary, our results show that defective loss and/or function of the LIFR in the LE adversely results in reduced numbers of implanting blastocysts. The levels of LIFR expression and its functional activity in the LE change during the preimplantation phase and suggest that incorrect expression/function of the LIFR during reproductive cycles maybe an additional factor contributing to infertility in human reproduction.
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###### 

**Antibody Table**

  **Peptide/Protein Target**       **Antigen Sequence (if Known)**   **Name of Antibody**      **Manufacturer, Catalog No., and/or Name of Individual Providing the Antibody**   **Species Raised in; Monoclonal or Polyclonal**   **Dilution Used**   **RRID**
  -------------------------------- --------------------------------- ------------------------- --------------------------------------------------------------------------------- ------------------------------------------------- ------------------- ------------
  LIFR (C19)                                                         Anti-LIFR                 Santacruz Biotechnology, sc-659                                                   Rabbit; polyclonal                                1:200 to 500        AB_2136105
  Phospho Y705 STAT3                                                 Anti-phospho Y705 STAT3   Bioworld Technology, BS4181                                                       Rabbit; polyclonal                                1:75 to 750         AB_1664102
  STAT3 (79D7)                                                       Anti-STAT3                Cell Signaling, catalog no. 4904S                                                 Rabbit; monoclonal                                1:50                AB_331269
  MSX1                                                               Anti-MSX1                 Abcam, ab73883                                                                    Mouse; monoclonal                                 1:500               AB_1269479
  Goat anti-rabbit IgG secondary                                     Anti-rabbit HRP           Dako, P0448                                                                       Goat; polyclonal                                  1:50                AB_2617138
  Alexa fluor secondary Ab                                           Anti-rabbit               A-11034                                                                           Goat; polyclonal                                  1:10                AB_2576217

Abbreviations: Ab, antibody; HRP, horseradish peroxidase; IgG, immunoglobulin G; RRID, Research Resource Identifier.
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